[1] |
DATTA G, FULLER BJ, DAVIDSON BR. Molecular mechanisms of liver ischemia reperfusion injury: insights from transgenic knockout models[J]. World J Gastroenterol, 2013, 19(11):1683-1698. DOI: 10.3748/wjg.v19.i11.1683.
|
[2] |
ZHAI Y, PETROWSKY H, HONG JC, et al. Ischaemia-reperfusion injury in liver transplantation--from bench to bedside[J]. Nat Rev Gastroenterol Hepatol, 2013, 10(2):79-89. DOI: 10.1038/nrgastro.2012.225.
|
[3] |
WOOLBRIGHT BL, JAESCHKE H. The impact of sterile inflammation in acute liver injury[J]. J Clin Transl Res, 2017, 3(Suppl 1):170-188. DOI: 10.18053/jctres.03.2017S1.003.
|
[4] |
PLOUFFE SW, MENG Z, LIN KC, et al. Characterization of Hippo pathway components by gene inactivation[J]. Mol Cell, 2016, 64(5):993-1008. DOI: 10.1016/j.molcel. 2016.10.034.
|
[5] |
YIMLAMAI D, FOWL BH, CAMARGO FD. Emerging evidence on the role of the Hippo/YAP pathway in liver physiology and cancer[J]. J Hepatol, 2015, 63(6):1491-1501. DOI: 10.1016/j.jhep.2015.07.008.
|
[6] |
PATEL SH, CAMARGO FD, YIMLAMAI D. Hippo signaling in the liver regulates organ size, cell fate, and carcinogenesis[J]. Gastroenterology, 2017, 152(3):533-545. DOI: 10.1053/j.gastro.2016.10.047.
|
[7] |
PARK JA, KWON YG. Hippo-YAP/TAZ signaling in angiogenesis[J]. BMB Rep, 2018, 51(3):157-162. doi: 10.5483/BMBRep.2018.51.3.016
|
[8] |
KANG LI, MARS WM, MICHALOPOULOS GK. Signals and cells involved in regulating liver regeneration[J]. Cells, 2012, 1(4):1261-1292. DOI: 10.3390/cells1041261.
|
[9] |
WANG Y, YU A, YU FX. The Hippo pathway in tissue homeostasis and regeneration[J]. Protein Cell, 2017, 8(5): 349-359. DOI: 10.1007/s13238-017-0371-0.
|
[10] |
RAO J, YUE S, FU Y, et al. ATF6 mediates a pro-inflammatory synergy between ER stress and TLR activation in the pathogenesis of liver ischemia-reperfusion injury[J]. Am J Transplant, 2014, 14(7):1552-1561. DOI: 10.1111/ajt.12711.
|
[11] |
JAESCHKE H, WOOLBRIGHT BL. Current strategies to minimize hepatic ischemia-reperfusion injury by targeting reactive oxygen species[J]. Transplant Rev (Orlando), 2012, 26(2):103-114. DOI: 10.1016/j.trre.2011.10.006.
|
[12] |
FRANCIS A, BAYNOSA R. Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms[J]. Diving Hyperb Med, 2017, 47(2):110-117. http://cn.bing.com/academic/profile?id=1668a9239048b784c5994d9f77ad3841&encoded=0&v=paper_preview&mkt=zh-cn
|
[13] |
MUKHOPADHYAY P, HORVÁTH B, ZSENGELLĖR Z, et al. Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential of mitochondrially targeted antioxidants[J]. Free Radic Biol Med, 2012, 53(5):1123-1138. DOI: 10.1016/j.freeradbiomed.2012.05.036.
|
[14] |
JU C, TACKE F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies[J]. Cell Mol Immunol, 2016, 13(3):316-327. DOI: 10.1038/cmi.2015.104.
|
[15] |
LU L, ZHOU H, NI M, et al. Innate immune regulations and liver ischemia-reperfusion injury[J]. Transplantation, 2016, 100(12):2601-2610. doi: 10.1097/TP.0000000000001411
|
[16] |
LU TF, YANG TH, ZHONG CP, et al. Dual effect of hepatic macrophages on liver ischemia and reperfusion injury during liver transplantation[J]. Immune Netw, 2018, 18(3):e24. DOI: 10.4110/in.2018.18.e24.
|
[17] |
LV Y, KIM K, SHENG Y, et al. YAP controls endothelial activation and vascular inflammation through TRAF6[J]. Circ Res, 2018, 123(1):43-56. DOI: 10.1161/CIRCRESAHA.118.313143.
|
[18] |
LEE KK, YONEHARA S. Identification of a mechanism that couples multisite phosphorylation of Yes-associated protein (YAP) with transcriptional coactivation and regulation of apoptosis[J]. J Biol Chem, 2016, 291(9): 4844-4845. DOI: 10.1074/jbc.A111.296954.
|
[19] |
FENG J, LI H, ZHANG Y, et al. Mammalian STE20-like kinase 1 deletion alleviates renal ischaemia-reperfusion injury via modulating mitophagy and the AMPK-YAP signalling pathway[J]. Cell Physiol Biochem, 2018, 51(5):2359-2376. DOI: 10.1159/000495896.
|
[20] |
COSSET É, ILMJÄRV S, DUTOIT V, et al. Glut3 addiction is a druggable vulnerability for a molecularly defined subpopulation of glioblastoma[J]. Cancer Cell, 2017, 32(6):856-868. DOI: 10.1016/j.ccell.2017.10.016.
|
[21] |
LI X, YAO W, YUAN Y, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma[J]. Gut, 2017, 66(1):157-167. DOI: 10.1136/gutjnl-2015-310514.
|
[22] |
BAECK C, WEHR A, KARLMARK KR, et al. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury[J]. Gut, 2012, 61(3):416-426. DOI: 10.1136/gutjnl-2011-300304.
|
[23] |
PYONTECK SM, AKKARI L, SCHUHMACHER AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression[J]. Nat Med, 2013, 19(10): 1264-1272. DOI: 10.1038/nm.3337.
|
[24] |
HUANG YJ, YANG CK, WEI PL, et al. Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways[J]. J Hematol Oncol, 2017, 10(1):60. DOI: 10.1186/s13045-017-0421-3.
|
[25] |
LI C, JIN Y, WEI S, et al. Hippo signaling controls NLR family pyrin domain containing 3 activation and governs immunoregulation of mesenchymal stem cells in mouse liver injury[J]. Hepatology, 2019, 70(5):1714-1731. DOI: 10.1002/hep.30700.
|